tiprankstipranks
Trending News
More News >
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Hong Kong Market
Advertisement

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Stock Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

9989 Financial Forecast

9989 Earnings Forecast

Next quarter’s earnings estimate for 9989 is HK$0.02 with a range of HK$0.02 to HK$0.02. The previous quarter’s EPS was HK$0.11. 9989 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year 9989 has Outperformed its overall industry.
Next quarter’s earnings estimate for 9989 is HK$0.02 with a range of HK$0.02 to HK$0.02. The previous quarter’s EPS was HK$0.11. 9989 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year 9989 has Outperformed its overall industry.

9989 Sales Forecast

Next quarter’s sales forecast for 9989 is HK$1.37B with a range of HK$1.37B to HK$1.37B. The previous quarter’s sales results were HK$1.48B. 9989 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 9989 has Outperformed its overall industry.
Next quarter’s sales forecast for 9989 is HK$1.37B with a range of HK$1.37B to HK$1.37B. The previous quarter’s sales results were HK$1.48B. 9989 beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 9989 has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on HK:9989
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$3.47HK$3.88
Sell
-41.48%
Downside
Reiterated
04/03/25
Shenzhen Hepalink Pharmaceutical Group (9989:HK) PT Raised to HK$3.88 at Goldman SachsGoldman Sachs analyst Ziyi Chen raised the price target on Shenzhen Hepalink Pharmaceutical Group (9989:HK) to HK$3.88 (from HK$3.47) while maintaining a Sell rating.
Morgan Stanley Analyst forecast on HK:9989
Laurence TamMorgan Stanley
Morgan Stanley
HK$3.7HK$3.5
Hold
-47.21%
Downside
Reiterated
09/17/24
Shenzhen Hepalink Pharmaceutical Group (9989:HK) PT Lowered to HK$3.50 at Morgan StanleyMorgan Stanley analyst Laurence Tam lowered the price target on Shenzhen Hepalink Pharmaceutical Group (9989:HK) to HK$3.50 (from HK$3.70) while maintaining a Equalweight rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on HK:9989
Ziyi ChenGoldman Sachs
Goldman Sachs
HK$3.47HK$3.88
Sell
-41.48%
Downside
Reiterated
04/03/25
Shenzhen Hepalink Pharmaceutical Group (9989:HK) PT Raised to HK$3.88 at Goldman SachsGoldman Sachs analyst Ziyi Chen raised the price target on Shenzhen Hepalink Pharmaceutical Group (9989:HK) to HK$3.88 (from HK$3.47) while maintaining a Sell rating.
Morgan Stanley Analyst forecast on HK:9989
Laurence TamMorgan Stanley
Morgan Stanley
HK$3.7HK$3.5
Hold
-47.21%
Downside
Reiterated
09/17/24
Shenzhen Hepalink Pharmaceutical Group (9989:HK) PT Lowered to HK$3.50 at Morgan StanleyMorgan Stanley analyst Laurence Tam lowered the price target on Shenzhen Hepalink Pharmaceutical Group (9989:HK) to HK$3.50 (from HK$3.70) while maintaining a Equalweight rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H

1 Month
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+2.15%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +2.15% per trade.
3 Months
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
-5.55%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -5.55% per trade.
1 Year
Ziyi ChenGoldman Sachs
Success Rate
0/2 ratings generated profit
0%
Average Return
-37.50%
reiterated a sell rating 4 months ago
Copying Ziyi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.50% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-69.55%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -69.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9989 Analyst Recommendation Trends

Rating
Sep 23
Oct 23
Sep 24
Apr 25
Strong Buy
0
0
0
0
Buy
0
0
0
0
Hold
1
1
2
1
Sell
0
1
1
2
Strong Sell
0
0
0
0
total
1
2
3
3
In the current month, 9989 has received 0 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. 9989 average Analyst price target in the past 3 months is 3.88.
Each month's total comprises the sum of three months' worth of ratings.

9989 Stock Forecast FAQ

What is HK:9989’s average 12-month price target, according to analysts?
Based on analyst ratings, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s 12-month average price target is 3.88.
    What is HK:9989’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for HK:9989, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H a Buy, Sell or Hold?
        Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a consensus rating of Moderate Sell, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s share price target?
          The average share price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is 3.88. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is HK$3.88 ,and the lowest forecast is HK$3.88. The average share price target represents -41.48% Decrease from the current price of HK$6.63.
            What do analysts say about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
            Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 0 Wall Streets Analysts.
              How can I buy shares of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
              To buy shares of HK:9989, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis